Decision may positively impact Company’s pipeline tests and companion treatment technologies
Salt Lake City, UT — (February 02, 2016) – Predictive Technology Group, Inc. (OTC PINK:PRED), a life sciences technology holding company, announced its subsidiary Predictive Therapeutics received a favorable ruling from the United States Patent and Trademark Office’s Patent Trial and Appeal Board (“PTAB”) on its spinal deformity molecular diagnostic tests and companion therapeutics (US Patent application 20150127105).
Mike Schramm, Predictive Therapeutics’ Director of Intellectual Property, said, “We are pleased that the Patent Trial and Appeal Board completely reversed the examiner and tacitly approved all twenty pending claims of the ‘105 application and we now look forward to a speedy allowance. The claims of the ‘105 application build on previously issued US patents 8,123,787 and 8,641,738 to which ‘105 claims priority and further bolster PRED’s Intellectual Property position.”
Bradley Robinson, PRED’s CEO added, “PRED is excited to move forward with the release of the subsidiary’s, Predictive Therapeutics, spinal deformity tests and begin development work on the companion therapeutics. Predictive Therapeutics is committed to providing our surgeon customers with the highest quality predictive diagnostics and treatment solutions that can ultimately benefit their patients.”
The Company believes that this favorable PTAB decision will have an impact on the other diagnostic tests and companion product candidates that are in our R&D pipeline.
About Predictive Technology Group, Inc.
Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat diseases.
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.